218 related articles for article (PubMed ID: 23108144)
41. Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141
Huang J; Zhou J; Ghinnagow R; Seki T; Iketani S; Soulard D; Paczkowski P; Tsuji Y; MacKay S; Cruz LJ; Trottein F; Tsuji M
Front Immunol; 2020; 11():2043. PubMed ID: 32973811
[TBL] [Abstract][Full Text] [Related]
42. NKT-Licensed In Vivo Dendritic Cell-Based Immunotherapy as Cellular Immunodrugs for Cancer Treatment.
Fujii SI; Shimizu K
Crit Rev Oncog; 2024; 29(1):45-61. PubMed ID: 38421713
[TBL] [Abstract][Full Text] [Related]
43. Invariant natural killer T cell-based immunotherapy for cancer.
Motohashi S; Nakayama T
Immunotherapy; 2009 Jan; 1(1):73-82. PubMed ID: 20635975
[TBL] [Abstract][Full Text] [Related]
44. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Durgan K; Ali M; Warner P; Latchman YE
Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
[TBL] [Abstract][Full Text] [Related]
45. Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.
Stolk DA; de Haas A; Vree J; Duinkerken S; Lübbers J; van de Ven R; Ambrosini M; Kalay H; Bruijns S; van der Vliet HJ; de Gruijl TD; van Kooyk Y
Front Immunol; 2020; 11():990. PubMed ID: 32536918
[TBL] [Abstract][Full Text] [Related]
46. Transfer of mRNA Encoding Invariant NKT Cell Receptors Imparts Glycolipid Specific Responses to T Cells and γδT Cells.
Shimizu K; Shinga J; Yamasaki S; Kawamura M; Dörrie J; Schaft N; Sato Y; Iyoda T; Fujii S
PLoS One; 2015; 10(6):e0131477. PubMed ID: 26121617
[TBL] [Abstract][Full Text] [Related]
47. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.
Wolf BJ; Choi JE; Exley MA
Front Immunol; 2018; 9():384. PubMed ID: 29559971
[TBL] [Abstract][Full Text] [Related]
48. Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
Courtney AN; Thapa P; Singh S; Wishahy AM; Zhou D; Sastry J
Eur J Immunol; 2011 Nov; 41(11):3312-22. PubMed ID: 21818755
[TBL] [Abstract][Full Text] [Related]
49. Natural Killer T-cell Immunotherapy in Combination with Chemotherapy-Induced Immunogenic Cell Death Targets Metastatic Breast Cancer.
Gebremeskel S; Lobert L; Tanner K; Walker B; Oliphant T; Clarke LE; Dellaire G; Johnston B
Cancer Immunol Res; 2017 Dec; 5(12):1086-1097. PubMed ID: 29054890
[TBL] [Abstract][Full Text] [Related]
50. Enhancing T cell responses and tumour immunity by vaccination with peptides conjugated to a weak NKT cell agonist.
Compton BJ; Farrand KJ; Tang CW; Osmond TL; Speir M; Authier-Hall A; Wang J; Ferguson PM; Chan STS; Anderson RJ; Cooney TR; Hayman CM; Williams GM; Brimble MA; Brooks CR; Yong LK; Metelitsa LS; Zajonc DM; Godfrey DI; Gasser O; Weinkove R; Painter GF; Hermans IF
Org Biomol Chem; 2019 Jan; 17(5):1225-1237. PubMed ID: 30656346
[TBL] [Abstract][Full Text] [Related]
51. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
[TBL] [Abstract][Full Text] [Related]
52. Roles of NKT cells in cancer immunotherapy.
Bae EA; Seo H; Kim IK; Jeon I; Kang CY
Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410
[TBL] [Abstract][Full Text] [Related]
53. iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.
Corgnac S; Perret R; Zhang L; Mach JP; Romero P; Donda A
J Immunother Cancer; 2014; 2(1):39. PubMed ID: 25426294
[TBL] [Abstract][Full Text] [Related]
54. Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines.
Faveeuw C; Trottein F
Cancer Res; 2014 Mar; 74(6):1632-8. PubMed ID: 24599135
[TBL] [Abstract][Full Text] [Related]
55. Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge.
Singh S; Yang G; Schluns KS; Anthony SM; Sastry KJ
PLoS One; 2014; 9(3):e90001. PubMed ID: 24599269
[TBL] [Abstract][Full Text] [Related]
56. Innate Response to Human Cancer Cells with or without IL-2 Receptor Common γ-Chain Function in NOD Background Mice Lacking Adaptive Immunity.
Nishime C; Kawai K; Yamamoto T; Katano I; Monnai M; Goda N; Mizushima T; Suemizu H; Nakamura M; Murata M; Suematsu M; Wakui M
J Immunol; 2015 Aug; 195(4):1883-90. PubMed ID: 26170385
[TBL] [Abstract][Full Text] [Related]
57. Optimizing NKT cell ligands as vaccine adjuvants.
Carreño LJ; Kharkwal SS; Porcelli SA
Immunotherapy; 2014; 6(3):309-20. PubMed ID: 24762075
[TBL] [Abstract][Full Text] [Related]
58. The regulatory role of invariant NKT cells in tumor immunity.
McEwen-Smith RM; Salio M; Cerundolo V
Cancer Immunol Res; 2015 May; 3(5):425-35. PubMed ID: 25941354
[TBL] [Abstract][Full Text] [Related]
59. Invariant natural killer T cells: bridging innate and adaptive immunity.
Van Kaer L; Parekh VV; Wu L
Cell Tissue Res; 2011 Jan; 343(1):43-55. PubMed ID: 20734065
[TBL] [Abstract][Full Text] [Related]
60. Murine splenic CD4⁺ T cells, induced by innate immune cell interactions and secreted factors, develop antileukemia cytotoxicity.
Nelles ME; Moreau JM; Furlonger CL; Berger A; Medin JA; Paige CJ
Cancer Immunol Res; 2014 Nov; 2(11):1113-24. PubMed ID: 25154710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
